BioCryst Announced Data Showing Reductions In Attack Rates In HAE Patients with Normal C1-Inhibitor After Beginning ORLADEYO Treatment

6/2/24 10:46:30 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $BCRX alert in real time by email

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced new real-world evidence showing that patients with hereditary angioedema (HAE) who have normal C1-inhibitor (HAE-nC1-INH) level and function had a reduction in monthly attack rates after starting oral, once-daily ORLADEYO® (berotralstat). The data were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain.

Get the next $BCRX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BCRX

Date	Price Target	Rating	Analyst
11/20/2023	$10.00	Overweight	JP Morgan
9/18/2023	$9.00 → $10.00	Sector Perform → Outperform	RBC Capital Mkts
8/4/2023	$11.00	Hold → Buy	Jefferies
7/13/2023	$10.00	Neutral → Buy	BofA Securities
2/22/2023	$14.00	Hold → Buy	Needham
11/2/2022	$14.00 → $16.00	In-line → Outperform	Evercore ISI
8/5/2022		Outperform → Perform	Oppenheimer
8/5/2022	$14.00	Outperform → In-line	Evercore ISI

More analyst ratings

BioCryst Appoints Dr. Donald Fong Chief Medical Officer
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Donald S. Fong, MD, MPH, has been appointed as the company's new chief medical officer, effective immediately. Dr. Fong joins Dr. Helen Thackray, the company's chief research and development officer, and Dr. Bill Sheridan, the company's chief development officer, as physicians on the company's leadership team. "We continue to advance our pipeline of novel therapies to treat diseases with significant unmet needs, including programs in Netherton syndrome and diabetic macular edema that we expect will enter the clinic this year and next year, respectively. Dona
9/5/24 7:00:00 AM ET
$BCRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BioCryst Appoints Dr. Nancy Hutson as Chair of the Board
RESEARCH TRIANGLE PARK, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the appointment of Dr. Nancy Hutson as chair of its board of directors, effective immediately. "I am honored to succeed Bob Ingram. He was a model of effective board leadership for us. Our board is comprised of exceptional people with diverse experience and I am excited to continue working alongside them and the management team to deliver innovative new therapies to patients with rare diseases," said Dr. Hutson. Dr. Hutson was appointed to the board in January 2012, bringing over 30 years of experience as a seasoned professional and leader within the pharmaceutica
3/31/23 7:00:00 AM ET
$BCRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer
RESEARCH TRIANGLE PARK, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. today announced that Dr. Bill Sheridan will become chief development officer and will focus on advancing the company's significant pipeline of development candidates. Dr. Ryan Arnold has been appointed as the company's new chief medical officer. Dr. Arnold joins Dr. Sheridan and Dr. Helen Thackray, the company's chief research and development officer, as physicians on the company's leadership team. "Our research and development platform continues to generate exciting opportunities across multiple rare disease targets and Bill's deep knowledge of our portfolio and dedicated focus on our pipelin
9/14/22 4:01:10 PM ET
$BCRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$BCRX
Press Releases

Fastest customizable press release news feed in the world

BioCryst Launches ORLADEYO® (berotralstat) in Portugal
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Infarmed in Portugal has recommended ORLADEYO® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Portugal will have access to the first oral, once-daily therapy for the reduction of recurrent HAE attacks. "The positive Infarmed recommendation of ORLADEYO broadens access to modern prophylaxis, providing greater choice for prescribing physicians and potentially a better quality of life for HAE patients in Portugal," said Charlie Gayer, c
2/12/25 7:00:56 AM ET
$BCRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress
RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts featuring new clinical and real-world outcomes with oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) joint congress. Included among these is a late-breaking abstract that highlights the first presentation of results from the APeX-P trial evaluating oral, once-daily ORLADEYO in pediatric patients with HAE who are 2 to <12 years of age. The congress will ta
2/10/25 8:30:43 AM ET
$BCRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BioCryst to Report Fourth Quarter 2024 Financial Results on February 24
RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2024 financial results on Monday, February 24, 2025. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a gl
2/10/25 7:00:05 AM ET
$BCRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24
RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2024 financial results on Monday, February 24, 2025. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a gl
2/10/25 7:00:05 AM ET
$BCRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update
— Q3 2024 ORLADEYO net revenue of $116.3 million (+35.7 percent y-o-y) — — Full-year 2024 ORLADEYO revenue guidance adjusted to $430-$435 million (top end of prior guidance range) — — Company introduces full-year 2024 total product revenue guidance of $443-$448 million based on additional 2024 revenue from RAPIVAB — — BCX17725 for Netherton syndrome advances into the clinic — — Company generates GAAP operating profit of $7.7 million in third quarter ($24.9 million non-GAAP operating profit) — RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today reported financial results for the third quarter ended September 30, 2024, and p
11/4/24 7:00:00 AM ET
$BCRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BioCryst to Report Third Quarter 2024 Financial Results on November 4
RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2024 financial results on Monday, November 4, 2024. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a glob
10/21/24 7:00:23 AM ET
$BCRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

BioCryst Announced Data Showing Reductions In Attack Rates In HAE Patients with Normal C1-Inhibitor After Beginning ORLADEYO Treatment

Chat with this insight

Recent Analyst Ratings for $BCRX

$BCRX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

$BCRX SEC Filings

BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure

BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure

$BCRX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Commercial Officer Gayer Charles K was granted 125,950 shares and covered exercise/tax liability with 2,461 shares, increasing direct ownership by 41% to 423,546 units (SEC Form 4)

Chief R&D Officer Thackray Helen M. was granted 125,950 shares and covered exercise/tax liability with 6,096 shares, increasing direct ownership by 45% to 384,843 units (SEC Form 4)

Chief Financial Officer Doyle Anthony was granted 120,700 shares and covered exercise/tax liability with 2,461 shares, increasing direct ownership by 46% to 377,867 units (SEC Form 4)

$BCRX Leadership Updates

Live Leadership Updates

BioCryst Appoints Dr. Donald Fong Chief Medical Officer

BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer

$BCRX Press Releases

Fastest customizable press release news feed in the world

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

$BCRX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Levin Alan G bought $49,996 worth of shares (7,861 units at $6.36), increasing direct ownership by 21% to 44,951 units (SEC Form 4)

Aselage Steve bought $16,000 worth of shares (2,500 units at $6.40) (SEC Form 4)

Hutson Nancy J bought $31,900 worth of shares (5,000 units at $6.38), increasing direct ownership by 6% to 86,818 units (SEC Form 4)

$BCRX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$BCRX Financials

Live finance-specific insights

JP Morgan resumed coverage on BioCryst Pharma with a new price target

BioCryst Pharma upgraded by RBC Capital Mkts with a new price target

BioCryst Pharma upgraded by Jefferies with a new price target

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update

BioCryst to Report Third Quarter 2024 Financial Results on November 4

Recent Analyst Ratings for
$BCRX

$BCRX
Large Ownership Changes

$BCRX
SEC Filings

$BCRX
Insider Trading

$BCRX
Leadership Updates

$BCRX
Press Releases

$BCRX
Insider Purchases

$BCRX
Analyst Ratings

$BCRX
Financials